SAT493 Laser Ablation For Benign Thyroid Nodules: A Way To Treat And Still Preserve The Thyroid
Abstract Disclosure: N. Kalara: None. D.L. Bignoli: None. C.M. Acosta: None. A. Manzano: None. Introduction: Thyroid nodules in adults have a prevalence of 3-7% based on palpation and 20-76% based on ultrasound examination. The majority of which are benign but some increase in size causing compressi...
Saved in:
Published in | Journal of the Endocrine Society Vol. 7; no. Supplement_1 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
US
Oxford University Press
05.10.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Disclosure: N. Kalara: None. D.L. Bignoli: None. C.M. Acosta: None. A. Manzano: None.
Introduction: Thyroid nodules in adults have a prevalence of 3-7% based on palpation and 20-76% based on ultrasound examination. The majority of which are benign but some increase in size causing compressive symptoms or cosmetic concerns, thus, needing treatment. Laser ablation (LA) is a safe, non-surgical approach for the management of benign thyroid nodules now approved in the US. Nodule reduction is achieved through laser induced cytoreduction and tissue coagulation. Two benign FNA biopsies 3-6 months apart and a nodule size of more than 2.5 cm are some of the inclusion criteria for LA. We present a case of a benign thyroid nodule causing compressive symptoms where LA was done since the patient declined surgery. Case description: 76-year-old female with a history of type 2 diabetes mellitus, hypertension, and multinodular goiter for many years presented with concerns of neck fullness and discomfort for the past 6 months. Thyroid ultrasound confirmed a large dominant right complex nodule of 2.8 x 1.13 x 3 cm with a volume of 5 ml. Thyroid function test showed Thyroid stimulating hormone (TSH) 1.2 mIU/mL (0.40-4.50) and free T4 1.24 ng/dl (0.9-1.7). Two FNA biopsies done 3 months apart in the past were Bethesda II. Given the compressive symptoms due to a multinodular gland thyroidectomy was discussed as a treatment option with the patient which she declined. Hence, LA was discussed as an option for the largest nodule. The procedure was performed without complications. The nodule received 1450 Joules at 6 watts using one Elesta laser fiber. At the end of 2 months post-LA, thyroid ultrasound showed a significant reduction of the nodule with a current size of 1.5 x 1 x 1.6 cm and 1.4ml volume. She continued to be clinically and biochemically euthyroid with a total volume reduction close to 70% and complete resolution in compressive symptoms. Conclusion: Percutaneous laser ablation is a non-surgical, minimally invasive procedure to treat benign thyroid nodules that is now accessible in the US with promising results and a good safety profile. It is covered by insurance in various states. In our case the patient refused surgical intervention, thus, laser ablation was done that resulted in the resolution of her compressive symptoms without any complications. More awareness regarding the laser ablation procedure and its availability for patients is needed, especially in cases where preservation of the thyroid gland is desired. Reference: 1. Gambelunghe G, Stefanetti E, Avenia N, De Feo P. Percutaneous Ultrasound-Guided Laser Ablation of Benign Thyroid Nodules: Results of 10-Year Follow-Up in 171 Patients. J Endocr Soc. 2021 May 5;5(7):bvab081. doi: 10.1210/jendso/bvab081. PMID: 34159286; PMCID: PMC8212682.
Presentation Date: Saturday, June 17, 2023 |
---|---|
AbstractList | Abstract
Disclosure: N. Kalara: None. D.L. Bignoli: None. C.M. Acosta: None. A. Manzano: None.
Introduction: Thyroid nodules in adults have a prevalence of 3-7% based on palpation and 20-76% based on ultrasound examination. The majority of which are benign but some increase in size causing compressive symptoms or cosmetic concerns, thus, needing treatment. Laser ablation (LA) is a safe, non-surgical approach for the management of benign thyroid nodules now approved in the US. Nodule reduction is achieved through laser induced cytoreduction and tissue coagulation. Two benign FNA biopsies 3-6 months apart and a nodule size of more than 2.5 cm are some of the inclusion criteria for LA. We present a case of a benign thyroid nodule causing compressive symptoms where LA was done since the patient declined surgery. Case description: 76-year-old female with a history of type 2 diabetes mellitus, hypertension, and multinodular goiter for many years presented with concerns of neck fullness and discomfort for the past 6 months. Thyroid ultrasound confirmed a large dominant right complex nodule of 2.8 x 1.13 x 3 cm with a volume of 5 ml. Thyroid function test showed Thyroid stimulating hormone (TSH) 1.2 mIU/mL (0.40-4.50) and free T4 1.24 ng/dl (0.9-1.7). Two FNA biopsies done 3 months apart in the past were Bethesda II. Given the compressive symptoms due to a multinodular gland thyroidectomy was discussed as a treatment option with the patient which she declined. Hence, LA was discussed as an option for the largest nodule. The procedure was performed without complications. The nodule received 1450 Joules at 6 watts using one Elesta laser fiber. At the end of 2 months post-LA, thyroid ultrasound showed a significant reduction of the nodule with a current size of 1.5 x 1 x 1.6 cm and 1.4ml volume. She continued to be clinically and biochemically euthyroid with a total volume reduction close to 70% and complete resolution in compressive symptoms. Conclusion: Percutaneous laser ablation is a non-surgical, minimally invasive procedure to treat benign thyroid nodules that is now accessible in the US with promising results and a good safety profile. It is covered by insurance in various states. In our case the patient refused surgical intervention, thus, laser ablation was done that resulted in the resolution of her compressive symptoms without any complications. More awareness regarding the laser ablation procedure and its availability for patients is needed, especially in cases where preservation of the thyroid gland is desired. Reference: 1. Gambelunghe G, Stefanetti E, Avenia N, De Feo P. Percutaneous Ultrasound-Guided Laser Ablation of Benign Thyroid Nodules: Results of 10-Year Follow-Up in 171 Patients. J Endocr Soc. 2021 May 5;5(7):bvab081. doi: 10.1210/jendso/bvab081. PMID: 34159286; PMCID: PMC8212682.
Presentation Date: Saturday, June 17, 2023 Disclosure: N. Kalara: None. D.L. Bignoli: None. C.M. Acosta: None. A. Manzano: None. Introduction : Thyroid nodules in adults have a prevalence of 3-7% based on palpation and 20-76% based on ultrasound examination. The majority of which are benign but some increase in size causing compressive symptoms or cosmetic concerns, thus, needing treatment. Laser ablation (LA) is a safe, non-surgical approach for the management of benign thyroid nodules now approved in the US. Nodule reduction is achieved through laser induced cytoreduction and tissue coagulation. Two benign FNA biopsies 3-6 months apart and a nodule size of more than 2.5 cm are some of the inclusion criteria for LA. We present a case of a benign thyroid nodule causing compressive symptoms where LA was done since the patient declined surgery. Case description : 76-year-old female with a history of type 2 diabetes mellitus, hypertension, and multinodular goiter for many years presented with concerns of neck fullness and discomfort for the past 6 months. Thyroid ultrasound confirmed a large dominant right complex nodule of 2.8 x 1.13 x 3 cm with a volume of 5 ml. Thyroid function test showed Thyroid stimulating hormone (TSH) 1.2 mIU/mL (0.40-4.50) and free T4 1.24 ng/dl (0.9-1.7). Two FNA biopsies done 3 months apart in the past were Bethesda II. Given the compressive symptoms due to a multinodular gland thyroidectomy was discussed as a treatment option with the patient which she declined. Hence, LA was discussed as an option for the largest nodule. The procedure was performed without complications. The nodule received 1450 Joules at 6 watts using one Elesta laser fiber. At the end of 2 months post-LA, thyroid ultrasound showed a significant reduction of the nodule with a current size of 1.5 x 1 x 1.6 cm and 1.4ml volume. She continued to be clinically and biochemically euthyroid with a total volume reduction close to 70% and complete resolution in compressive symptoms. Conclusion : Percutaneous laser ablation is a non-surgical, minimally invasive procedure to treat benign thyroid nodules that is now accessible in the US with promising results and a good safety profile. It is covered by insurance in various states. In our case the patient refused surgical intervention, thus, laser ablation was done that resulted in the resolution of her compressive symptoms without any complications. More awareness regarding the laser ablation procedure and its availability for patients is needed, especially in cases where preservation of the thyroid gland is desired. Reference: 1. Gambelunghe G, Stefanetti E, Avenia N, De Feo P. Percutaneous Ultrasound-Guided Laser Ablation of Benign Thyroid Nodules: Results of 10-Year Follow-Up in 171 Patients. J Endocr Soc. 2021 May 5;5(7):bvab081. doi: 10.1210/jendso/bvab081. PMID: 34159286; PMCID: PMC8212682. Presentation Date: Saturday, June 17, 2023 |
Author | Kalara, Niketa Manzano, Alex Maria Bignoli, Daniela Laura Acosta, Crystal Maria |
Author_xml | – sequence: 1 givenname: Niketa surname: Kalara fullname: Kalara, Niketa – sequence: 2 givenname: Daniela Laura surname: Maria Bignoli fullname: Maria Bignoli, Daniela Laura – sequence: 3 givenname: Crystal Maria surname: Acosta fullname: Acosta, Crystal Maria – sequence: 4 givenname: Alex surname: Manzano fullname: Manzano, Alex |
BookMark | eNpVkF9LwzAUR4MoOOc-gS_5At3yr2vji9ThVBgqrOJjSJrbraNLRtIN9u3d2BR9uj-4nPNwbtCl8w4QuqNkSBkloxU4G_3I7LSlVAypHI8vUI-JjCVUZuzyz75GgxhXhBAquZBC9JCaF6WQHM90hIAL0-qu8Q5PfcCP4JqFw-VyH3xj8Zu32xbiPS7wl97j0uMygO5w4Syed03b4o8AB8kODgj8YLfoqtZthMH59tHn9KmcvCSz9-fXSTFLKirScVJXRnOTQ51RkuUpz3NSS2CpzgUwyytta17nMqNaCmaYTUlljTCESWIZyTTvo4eTd7M1a7AVuC7oVm1Cs9Zhr7xu1P-Pa5Zq4XeKkjQVOZcHAz8ZquBjDFD_wpSoY2h1Cq3OodUxNP8GvBB2EA |
ContentType | Journal Article |
Copyright | The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. 2023 |
Copyright_xml | – notice: The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. 2023 |
DBID | AAYXX CITATION 5PM |
DOI | 10.1210/jendso/bvad114.1966 |
DatabaseName | CrossRef PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2472-1972 |
ExternalDocumentID | 10_1210_jendso_bvad114_1966 |
GroupedDBID | 0R~ 53G AAFWJ AAPPN AAPXW AAVAP AAYXX ABPTD ABXVV ACGFS ADBBV AENZO AFPKN AFULF ALMA_UNASSIGNED_HOLDINGS AOIJS BAYMD BCNDV BTTYL CITATION EBS EMOBN GROUPED_DOAJ HYE IAO ITC KQ8 KSI ML0 M~E O9- OK1 ROX RPM TJX TOX 5PM |
ID | FETCH-LOGICAL-c1456-fcba3b8ef7107853880f9e25a84e2d3cadf3f8971a942b2d50cdb4b0290d207a3 |
IEDL.DBID | RPM |
ISSN | 2472-1972 |
IngestDate | Tue Sep 17 21:29:26 EDT 2024 Thu Sep 26 15:59:52 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement_1 |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c1456-fcba3b8ef7107853880f9e25a84e2d3cadf3f8971a942b2d50cdb4b0290d207a3 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554839/ |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10554839 crossref_primary_10_1210_jendso_bvad114_1966 |
PublicationCentury | 2000 |
PublicationDate | 2023-10-05 20231005 |
PublicationDateYYYYMMDD | 2023-10-05 |
PublicationDate_xml | – month: 10 year: 2023 text: 2023-10-05 day: 05 |
PublicationDecade | 2020 |
PublicationPlace | US |
PublicationPlace_xml | – name: US |
PublicationTitle | Journal of the Endocrine Society |
PublicationYear | 2023 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
SSID | ssj0001934944 |
Score | 2.2766948 |
Snippet | Abstract
Disclosure: N. Kalara: None. D.L. Bignoli: None. C.M. Acosta: None. A. Manzano: None.
Introduction: Thyroid nodules in adults have a prevalence of... Disclosure: N. Kalara: None. D.L. Bignoli: None. C.M. Acosta: None. A. Manzano: None. Introduction : Thyroid nodules in adults have a prevalence of 3-7% based... |
SourceID | pubmedcentral crossref |
SourceType | Open Access Repository Aggregation Database |
SubjectTerms | Thyroid |
Title | SAT493 Laser Ablation For Benign Thyroid Nodules: A Way To Treat And Still Preserve The Thyroid |
URI | https://pubmed.ncbi.nlm.nih.gov/PMC10554839 |
Volume | 7 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwGA3bHsQX8YrzMvLgo916SZvGtzocIm4K63BvJWkSV5mtjCn47_3Si9hXX0qhfNCepJzztScnCF0R6YQqVI6llQosYDzfErbSFteUMy5MYLhpFKez4H5BHpb-soOCZi1MadpPRTbM1-_DPFuV3sqP93TU-MRGz9Ox2dSRALOPuqhLPe9Pj15-WWEmcoXUEUNmicqbcZcWI_HFJcj_IUy6oEVDbTvkH36Z7KO9WhjiqLqBA9RR-SHamda_vo9QMo9iwjz8CLSzwZGoPGx4Umzwrcqz1xzHq-9NkUk8K-QnPMINjvAL_8ZxgWOjDHGUSzzfZus1Nr4L43SEEtWUHaPF5C4e31v17ghW6oDqsXQquCdCpUEjUCBdeBE1U67PQ6Jc6aVcak-HjDqcEVe40rdTKYiwXWZL16bcO0G9vMjVKcJUOgET2ucgV4hHbUbhjBAZgHwkKad9dN2AlXxUIRiJaR4A26TCNqmxTQy2fRS2AP2tMVHW7SswwmWkdTOiZ_8vPUe7Ziv40mjnX6DedvOpLkEwbMWgbLQH5SyBY_y0_AF_TMXs |
link.rule.ids | 230,315,733,786,790,870,891,27957,27958,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwEB0BlYBLaYGqfLT40GOTzYcTx9wCYrWlu6tKBMEtsmMb0i4JWu1Wgl_POB8V21t7i2SNbOXZmjfJ8xuAL1T5iU607xitYwczXuRITxtHGCa4kNYw3BaKk2k8uqaXt9HtGsT9XZhGtF_I0q1mD25V3jfayseHYtDrxAY_Jue2qSPFzD5Yhzd4YAP2qkpvvq1wa7pCO5Mhe0nlp9WX1gP5WygsAFzcdvFKIloVRL7KMMMduOnX1gpLfrnLhXSL579sG_998e_gbUc6SdqOv4c1Xe3C5qT7rb4H-VWaUR6SMaa0OUllq48jw3pOznRV3lUku3-a16Ui01otcYZTkpIb8USymmSWdZK0UuRqUc5mxGo6rIoSQ3Qftg_Xw4vsfOR0nRecwkdG5ZhCilAm2iD_YJjQ8ZAbroNIJFQHKiyEMqFJOPMFp4EMVOQVSlLpBdxTgcdE-AE2qrrSH4Ew5cdcmkggFaIh8zjDJ0pVjNSUFoIdwNcehvyxNdjIbWGCqOUtanmHWm5RO4BkBao_MdYme3UEAWjssvsXfvj_oSewNcom43z8bfr9CLZty_lG0Bcdw8ZivtSfkJgs5OdmF74AJRDmBw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JT9wwGLUoSKgXli6CsvnQY7M7i3sLywjamRHSZFSkHiI7tiEwOKPpTCX49XzOgmY4couUfMrybL33JS_PCH0nwktkIj1LSRlZwHihxV2pLKZiRhk3geGmURwMo8sx-XUT3rSuyn-trVIXvLT15NHW5V3trZw-Fk7nE3OuB2dmUUcCzO5MhXI-oA2YtD5d6tTr9yvUBK-QNmjI_KhybzymlcP_MwFNgA1DL1oho1VT5BLL9LbR3-76GnPJg72Yc7t4fhPd-L4b2EFbrfjEaXPMLlqT-hPaHLSf1z-jfJRmhAa4D9Q2wylvfHK4V83wqdTlrcbZ3dOsKgUeVmIBZ_mJU_yHPeGswplRnzjVAo_m5WSCjbfDuCmhRHZlX9C4d5GdXVrtCgxW4YGyslTBWcATqUCHxEDsMNkVlX7IEiJ9ERRMqEAlNPYYJT73RegWghPu-tQVvhuz4Cta15WWewjHwosoVyEDSUSC2KUxbBEiIpCopGDxPvrRQZFPm6CN3DQogFzeIJe3yOUGuX2UrMD1WmPislf3AAh1bHb30L-9v_QEbV6f9_L-1fD3AfpoVp6vfX3hIVqfzxbyCPTJnB_XA_EFaRrohw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SAT493+Laser+Ablation+For+Benign+Thyroid+Nodules%3A+A+Way+To+Treat+And+Still+Preserve+The+Thyroid&rft.jtitle=Journal+of+the+Endocrine+Society&rft.au=Kalara%2C+Niketa&rft.au=Maria+Bignoli%2C+Daniela+Laura&rft.au=Acosta%2C+Crystal+Maria&rft.au=Manzano%2C+Alex&rft.date=2023-10-05&rft.issn=2472-1972&rft.eissn=2472-1972&rft.volume=7&rft.issue=Supplement_1&rft_id=info:doi/10.1210%2Fjendso%2Fbvad114.1966&rft.externalDBID=n%2Fa&rft.externalDocID=10_1210_jendso_bvad114_1966 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2472-1972&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2472-1972&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2472-1972&client=summon |